Peak Bio, Inc.

Peak Bio, Inc. (Nasdaq: PKBO) is a clinical-stage biopharmaceutical company focused on oncology, developing antibody-drug conjugate therapeutics targeting solid tumors. The company completed its SPAC merger and began trading in 2022, with its November 2022 Form 10-Q reflecting its first months as a publicly listed entity. Operating in the healthcare and life sciences sector, Peak Bio was pursuing a pipeline of cancer treatments at the time of filing, with its lead programs aimed at addressing unmet needs in oncology. The company's post-merger disclosures offer a window into the challenges clinical-stage biotechs face following a de-SPAC transition. For full filing history, pipeline data, and sponsor details on PKBO, sign up for complete access at SpacDesk.